Lenvatinib plus Tislelizumab vs Lenvatinib alone for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic liver cancer that cannot be removed by surgery.
- Your cancer got worse after previous treatment with an anti-PD1/PD-L1 drug combined with bevacizumab.
- You are at least 18 years old.
- You have at least one tumor that can be measured on a scan and has not been treated locally, or if treated, has grown since.
- Your liver function is fairly good (Child-Pugh score 5-7) and you are able to care for yourself (ECOG 0-2).
- If you have chronic hepatitis B, your viral load must be low and you must be on antiviral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two or three drugs for advanced liver cancer that cannot be removed with surgery. The goal is to see if adding a third drug (gefitinib) to the standard two-drug combination helps patients live longer with better quality of life.
This study looks at combining TACE (a procedure that delivers chemotherapy directly to the liver) with two newer drugs — tislelizumab (immunotherapy) and lenvatinib (targeted therapy) — for people with advanced liver cancer. The goal is to see how well this combination works when used together.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This study tests a combination of two drugs—lenvatinib (a targeted therapy that blocks blood vessel growth) and tislelizumab (an immunotherapy that helps your immune system fight cancer)—in people with advanced liver cancer who also have hepatitis B. The goal is to see if this combination can shrink tumors or slow the cancer's growth, and to find biomarkers (clues in your blood or tissue) that predict who will benefit.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.